Global Polymixin B Market Size By Type (Polymixin API, Polymixin Premix), By Application (Pigs, Chickens), By Region, And Segment Forecasts, 2023 to 2032

The Global Polymyxin B Market was valued at USD 315 million in 2023 and is projected to reach USD 512 million by 2031, expanding at a CAGR of 6.2% during the forecast period from 2023 to 2031. The rising incidence of multidrug-resistant (MDR) bacterial infections, especially those caused by Gram-negative organisms, is a primary driver of market growth. Polymyxin B, a last-resort antibiotic, is increasingly being utilized in critical care and infectious disease settings. The resurgence in the use of polymyxins stems from the growing limitations of conventional antibiotics and the urgent need for effective antimicrobial agents against resistant pathogens.

Drivers:

1. Growing Prevalence of Drug-Resistant Infections:

The rapid global spread of antimicrobial resistance (AMR) has elevated the demand for potent antibiotics like polymyxin B. Hospitals, particularly intensive care units (ICUs), are increasingly turning to polymyxin B to manage life-threatening infections where other antibiotics fail.

2. Increased Use in Critical Care Settings:

Polymyxin B is often used for hospital-acquired infections such as ventilator-associated pneumonia (VAP) and bloodstream infections (BSIs), making it a staple in critical care protocols.

3. Supportive Regulatory Environment:

Health authorities such as the WHO and CDC are emphasizing the importance of addressing AMR through effective antibiotic stewardship and availability of last-line agents like polymyxin B, encouraging more strategic utilization.

Restraints:

1. Nephrotoxicity and Neurotoxicity Risks:

Polymyxin B is associated with adverse effects, particularly kidney toxicity. This limits its broader usage and mandates cautious dosing and monitoring, especially in vulnerable populations.

2. Availability of Alternative Therapies in Certain Regions:

The emergence of newer, less toxic antibiotic combinations may moderate the demand for polymyxin B in some developed regions where advanced therapies are more accessible.

Opportunity:

1. Increasing R&D Investments in Novel Formulations:

Pharmaceutical companies are investing in developing safer polymyxin B formulations, including liposomal or inhaled variants, which may expand its therapeutic potential and patient safety.

2. Expansion in Emerging Healthcare Markets:

Countries across Asia-Pacific, Latin America, and Africa are witnessing a rise in MDR bacterial cases, creating a demand surge for accessible and affordable last-line antibiotics like polymyxin B.

Market by System Type Insights:

By formulation, injectable polymyxin B dominated the market in 2023 due to its critical role in systemic infections, particularly in ICU settings. This segment benefits from its fast onset of action and high efficacy in bloodstream and pulmonary infections. Meanwhile, the topical formulation segment is anticipated to witness steady growth, supported by use in ophthalmic and dermal infections.

Market by End-Use Insights:

The hospital pharmacies segment held the largest revenue share in 2023, as polymyxin B is primarily dispensed for inpatient care in tertiary hospitals and ICUs. The retail pharmacy segment is expected to grow gradually, particularly in countries where polymyxin B is also prescribed for localized infections treated outside the hospital setting.

Market by Regional Insights:

North America accounted for the largest share in 2023, driven by a high burden of MDR infections, strong clinical adoption in ICUs, and established antimicrobial stewardship programs. Asia-Pacific is projected to be the fastest-growing region, owing to increasing healthcare expenditure, high infection rates, and growing awareness around AMR solutions in countries like China and India.

Competitive Scenario:

Key players in the global polymyxin B market include Pfizer Inc., Xellia Pharmaceuticals, Cipla Limited, Sandoz (a Novartis division), Apotex Inc., and Endo International plc. These companies are actively pursuing regulatory approvals, expanding production capacities, and investing in R&D for next-generation polymyxin B formulations.

Key Developments:

2023: Xellia Pharmaceuticals expanded its U.S.-based manufacturing facility to scale up polymyxin B production in response to rising demand from hospitals.

2024: Cipla launched a new polymyxin B formulation in India with improved pharmacokinetics to reduce nephrotoxicity risks.

2025: Sandoz received regulatory clearance in Europe for a liposomal polymyxin B formulation aimed at targeted lung infection therapy.

Scope of Work – Global Polymyxin B Market

Report Metric Details

Market Size (2023) USD 315 million

Projected Market Size (2031) USD 512 million

CAGR (2023–2031) 6.2%

Market Segments By Formulation (Injectable, Topical), By End-Use (Hospital Pharmacies, Retail Pharmacies)

Growth Drivers Rising MDR infections, ICU demand, regulatory support

Opportunities R&D in safer formulations, emerging markets expansion

FAQs:

1) What is the current market size of the Global Polymyxin B Market?

The market was valued at USD 315 million in 2023.

2) What is the major growth driver of the Global Polymyxin B Market?

The increasing prevalence of multidrug-resistant infections globally is the major driver.

3) Which is the largest region during the forecast period in the Global Polymyxin B Market?

North America held the largest market share in 2023 and is expected to maintain its lead.

4) Which segment accounted for the largest market share in Global Polymyxin B Market?

The injectable formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Polymyxin B Market?

Key players include Pfizer Inc., Xellia Pharmaceuticals, Cipla Limited, Sandoz, Apotex Inc., and Endo International plc.